ARTV
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics (ARTV) Q2 2026 earnings
Published Aug 6, 2026
AI summary
- GAAP EPS −$0.63 beat the −$0.64 consensus by $0.01, up from −$0.87 a year ago.
- Artiva reported a net loss of $25 million for the second quarter of 2026.
- The company ended the quarter with $349.4 million in cash and investments, bolstered by a recent stock offering.
- The FDA granted RMAT designation to the company's lead therapy, AlloNK, for refractory rheumatoid arthritis.
- A Phase 3 registrational trial for AlloNK in refractory rheumatoid arthritis is set to begin in late 2026.
Results vs analyst consensus
Revenue
Not reported in this release.
EPS · GAAP (street basis)
Reported · Diluted EPS (GAAP, street basis)
−$0.63
Consensus −$0.64
Beat by $0.01GAAP EPS: −$0.63
Consensus: Yahoo Finance · Q2 2026 · EPS estimate at release
Revenue display rounded; difference uses exact result.
Next quarter outlook
No guidance in this release.
What to watch
- The company is a clinical-stage biotechnology firm and currently generates no revenue from product sales.
- Research and development expenses increased to $21.9 million compared to $17.9 million in the prior year period.
Read original report
Source: Artiva Biotherapeutics, Inc. press release · SEC Form 8-K exhibit 99.1